Skip to main content

Table 2 Baseline characteristics in concordant and discordant groups by medians (apoB and LDL-C)

From: Apolipoprotein B is associated with CT-angiographic progression beyond low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in patients with coronary artery disease

Variables

Low apoB/

Low LDL-C

Low apoB/

High LDL-C

High apoB/

Low LDL-C

High apoB/

High LDL-C

P value

N

181

82

91

190

 

Age, years

67.1 ± 10.1

66.0 ± 9.5

61.8 ± 11.0

62.5 ± 10.9

< 0.001

Male, n (%)

108 (59.7)

38 (46.3)

55 (60.4)

106 (55.8)

0.188

BMI, kg/m2

24.3 ± 3.0

24.2 ± 3.0

24.9 ± 2.9

25.1 ± 2.8

0.016

Hypertension, n (%)

133 (73.5)

63 (76.8)

59 (64.8)

140 (73.7)

0.298

Diabetes, n (%)

76 (42.0)

39 (47.6)

53 (58.2)

99 (52.1)

0.058

Obstructive CAD, n (%)

94 (51.9)

38 (46.3)

43 (47.3)

97 (51.1)

0.785

Smoking status, n (%)

55 (30.4)

19 (23.2)

30 (33.0)

67 (35.3)

0.253

SBP, mmHg

142.8 ± 18.4

143.5 ± 13.4

139.3 ± 16.6

142.3 ± 17.4

0.346

DBP, mmHg

77.1 ± 10.8

78.1 ± 8.0

78.1 ± 10.1

79.5 ± 9.9

0.150

WBC count, ×10E9/L

6.98 ± 1.66

6.79 ± 1.72

6.92 ± 2.00

7.00 ± 1.41

0.797

Creatinine, µmol/L

80.22 ± 19.83

73.33 ± 22.73

81.83 ± 21.72

77.27 ± 19.64

0.024

eGFR, mL/min/1.73m2

79.42 ± 17.34

84.48 ± 15.16

81.50 ± 20.12

84.03 ± 17.22

0.044

Uric acid, mmol/L

363.46 ± 111.93

349.62 ± 112.74

382.03 ± 103.10

398.35 ± 106.43

0.002

FPG, mmol/L

6.24 ± 4.29

6.27 ± 2.52

6.99 ± 2.94

6.77 ± 3.19

0.253

HbA1c, (%)

6.60 ± 1.67

6.60 ± 1.50

6.92 ± 1.71

6.94 ± 1.86

0.162

TC, mmol/L

4.00 ± 0.88

5.21 ± 0.79

4.61 ± 0.94

5.83 ± 0.87

< 0.001

TG, mmol/L

1.16 (0.85, 1.64)

1.38 (1.01, 1.89)

2.30 (1.39, 3.43)

1.72 (1.31, 2.41)

< 0.001

HDL-C, mmol/L

1.16 ± 0.31

1.19 ± 0.32

0.98 ± 0.26

1.14 ± 0.26

< 0.001

LDL-C, mmol/L

2.24 ± 0.48

3.54 ± 0.46

2.45 ± 0.46

3.98 ± 0.70

< 0.001

Lipoprotein(a), mg/L

124.00 (66.00, 235.35)

163.40 (82.83, 288.20)

104.00 (50.30, 173.30)

132.15 (76.98, 278.23)

0.004

Non-HDL-C, mmol/L

1.16 ± 0.31

1.19 ± 0.32

0.99 ± 0.26

1.14 ± 0.26

< 0.001

ApoB, g/L

0.74 ± 0.13

0.85 ± 0.12

1.33 ± 0.50

1.34 ± 0.26

< 0.001

Anti-platelet medication, n (%)

156 (86.2)

77 (93.9)

77 (84.6)

163 (85.8)

0.236

Statins, n (%)

160 (88.4)

67 (81.7)

73 (80.2)

166 (87.4)

0.188

β-blocker, n (%)

78 (43.1)

34 (41.5)

29 (31.9)

77 (40.5)

0.345

ACEI/ARB, n (%)

111 (61.3)

51 (62.2)

49 (53.8)

106 (55.8)

0.488

Glucose-lowering therapy, n (%)

61 (33.7)

37 (45.1)

42 (46.2)

80 (42.1)

0.132

Initial GS

7.0 (4.3, 13.0)

5.0 (3.0,12.0)

6.0 (3.0, 12.0)

7.3 (4.0, 15.0)

0.295

  1. Data are mean ± SD, or median with interquartile range, or frequencies with percentage, as appropriate
  2. ApoB apolipoprotein B, BMI body mass index, CAD coronary artery disease, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white cell counts, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HbA1c hemoglobinA1c, TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, GS Gensini Score
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X